Montevideo, Uruguay October 24, 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced a realignment of its management structure to better suit the company´s strategy. To gain speed and focus on new launches in key geographies Mr. Mariano García-Valiño (CEO of Grupo Biotoscana) will take direct responsibility for overseeing Brazil and Argentina, the two largest operations of the company. At the same time, the company is creating the position of Executive Vice President (EVP), Andean Region, which will be filled by GBT-veteran, Ms. Julieta Serna. This new position will be responsible for leading operations in Bolivia, Colombia, Chile, Ecuador, Mexico, Paraguay, Peru and Uruguay, reporting directly to Mr. García-Valiño. As a result, Mr. Jorge Ramos will leave the company.
“This will allow us to re-focus our priorities against our most important opportunities.”, said Mr. Garcia-Valino in an internal communication. “As you know, we have recently announced a deal with EISAI, which gives us immediate access to 2 assets in Mexico and 4 in Brazil. At the same time, we have opportunity of launching Zevtera in Argentina in Q1 and Mexico has a good problem: it needs to accelerate to launch not one product, but three. Our focus on materializing our pipeline needs to be paramount”.
Ms. Serna, a member of the original team that conceptualized the company together with Mr. Garcia-Valino at Advent International, has been instrumental in GBT’s development in several fronts. Most recently, she was the company’s Chief Strategy Officer. The company is in the final stages of recruiting to replace Julieta’s old position. In the meantime, Nuno Toscano, from Advent’s Portfolio Support Group, to temporarily fill the role.”
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products.
To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com